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Abstract:  
Homocysteine, a metabolite from methionine breakdown, can have detrimental effects to 
multiple systems in the human body. Methionine is naturally acquired from diet and if too much 
is consumed, as in diets with high red meats, the metabolic system becomes overloaded leading 
to elevated blood levels of homocysteine. This condition is called hyperhomocysteinemia (Hcy). 
Hyperhomocysteinemia is also related to aging and several genetic factors which ensure its 
proper regulation. More importantly, hyperhomocysteinemia has been shown as a risk factor to 
numerous disease states including cardiovascular disease and in neuropsychiatric illness. With 
respect to cardiovascular pathology, it has been found from the results of 80 clinical studies 
which sampled around 10,000 patients that elevated levels of homocysteine is linked with 
increased cardiovascular mortality rates. Along with Hcy’s effect on the cardiovascular system it 
has also been shown to induce neurological disorders in the form of neural tube defects, mental 
disorders, and cognitive impairment. From the literature I will explain plausible routes that Hcy 
affects vascular function and from data acquired during research conducted at the University of 
Louisville I will show it’s implication in memory impairment. The data also includes the 
possible treatment of sodium hydrogen sulfide to alleviate Hcy’s neurological effects.   
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I: What is Homocysteine?: 
Neurovascular and cardiovascular diseases are becoming increasingly prevalent as 
the population ages. Many of these diseases, including Alzheimer’s, stroke, Parkinson’s, 
depression, and dementia, have a link to elevated levels of homocysteine in the blood 
[1,2,3]. From the prevalence of these diseases, homocysteine’s negative effects need to be 
examined further. Homocysteine itself is a sulfur-containing, non-proteinogenic amino 
acid that is a by-product of normal methionine metabolism [4].  
Methionine is one of two sulfur containing essential amino acids and plays an 
important role in the proper function of many proteins. Methionine is normally consumed 
in high levels by eating red meats (0.843g/100g) and eggs (2.48g/100g), as well as a 
variety of nuts, fish, and poultry [5]. Because methionine contains sulfur it is prone to 
oxidation, but generally it is stabilized by hydrophobic interactions and is not highly 
nucleophilic like its sister molecule cysteine. Methionine is normally metabolized 
properly in most people, but the pathway seems to be less effective with aging and also 
with epigenetic factors such as poor diet and exercise [6]. The pathway and subsequent 
enzymes involved are shown below [Figure 1].  
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The alteration of the methionine pathway can lead to a buildup of homocysteine 
within the blood above normal concentrations, which is termed hyperhomocysteinemia. 
Normally, homocysteine is metabolized into two primary fates: it is either 
transmethylated back to methionine to assist the folate cycle or is transulfanated into 
cystathionine by CBS.  
The transmethylation pathway requires cyanocobalamin (B12), folate and the 
enzyme 5,10- methylenetetrahydrofolate reductase (MTHFR). Homocysteine acquires a 
methyl group from N-5-methyltetrahydrofolate (5-methyl THF) which is an intermediary 
in the folate cycle that occurs in all tissue and is dependent on cyanocobalamin (B12) 
[29]. After acquiring a methyl group homocysteine is converted into tetrahydrofolate 
(THF) and methionine by methionine synthase (MS) and cyanocobalamin (B12) [29]. 
There is another way homocysteine is remethylated but this primarily occurs in the liver 
Figure 1: Shown above is the basic methionine metabolic pathway. B12 (1) and folic acid (2) play key roles 
in proper breakdown. Under proper conditions homocysteine is converted back to methionine due to its 
essential nature.   
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and kidneys with betaine donating a methyl group by ways of betaine homocysteine S-
methyltransferase into dimethylglycine [30]. 
The transulfanation pathway entails the enzyme cystathionine beta-synthase 
(CBS) and pyridoxine (B6). The initial step in this pathway is the union of homocysteine 
and serine, catalyzed by cystathionine beta synthase, creating cystathionine [30]. For 
CBS, pyridoxine (B6) is an essential cofactor explaining increase of homocysteine with 
certain diets. Abnormalities of this pathway can also influence remethylation by stressing 
its capacity. When the folate cycle is overwhelmed it uses S-Adenosylmethioine (SAM) 
to re-convert back to methionine. In cases where methionine is concentrated, CBS and 
MTHFR are unavailable or ineffective, the system is overloaded leading to an 
accumulation of homocysteine. The basic metabolism of homocysteine is shown below 
[Figure 2].  
II: Common Causes of Alternating Homocysteine Levels: 
The progressions of homocysteine concentrations in human blood are as follows- 
normal: 8-15 μmol/L, moderate: 15-30 μmol/L, elevated: 30-100 μmol/L, and high: 100> 
Figure 2 
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μmol/L [7]. As previously stated these levels can vary upon several factors including: 
genetic factors, diet and exercise, age, gender, and smoking.  
Genetic factors can lead to the elevation of plasma homocysteine through the 
mutation or knockout of several enzymes. Children whose parents have had a history of 
cardiovascular disease tend to have higher levels of plasma homocysteine levels leading 
to the conclusion of inheritance. This increased risk is attributed to two main genetic 
factors: the alteration of the CBS and MTHFR genes. CBS, as previously mentioned, is 
essential for proper homocysteine metabolism. Homozygosity of for CBS deficiency is 
rare (1/300,000 births) and similarly, heterozygosity for CBS occurs in less than 1% of 
the population [11]. Homozygosity of CBS causes severe hyperhomocystemia and CBS 
heterozygosity causes mild hyperhomocystemia and is why CBS +/- knockout mice are 
common experimental models.  
Methyltetrahydrofolate reductase (MTHR) is also important to proper re-
conversion of homocysteine to methionine and its modification can cause increased 
homocysteine levels as well.  The C677T mutation of the MTHFR gene is more common 
than CBS issues and occurs in 35-39% of the Caucasian North American population and 
leads to a predisposition towards vitamin deficiencies and elevated homocysteine levels 
[12]. The C677T homozygous mutation occurs in 10-15% of the population and leads to 
a threefold increase in cardiovascular risk. The heterozygous mutation of C677T is more 
prevalent at 22-25% of the population, but only leads to moderate increases in plasma 
homocysteine levels in individuals lacking proper diet [12, 13]. 
Diet and exercise also play a role in elevated homocysteine levels. Diet seems to 
play a significant role in managing homocysteine levels while the impact of exercise is 
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less clear. Increased intake of foods containing higher levels of folic acid, 
cyanocobalamin (B12), and pyridoxine (B6) will reduce blood levels of homocysteine 
regardless of pre-diet levels [11, 14].  
Dr. Kilmer McCully MD in his book, The Homocysteine Revolution, presents a 
strong argument for proper diet in reducing both homocysteine and prominence of 
vascular issues. He argues that in developed countries diets are full of processed foods 
which knowingly are short in pyridoxine (B6) and folic acid due to their sensitively 
towards destruction in food processing; for example in the refining and preservation of 
wheat into white flour, 50-90% of pyridoxine (B6) is destroyed, and in the canning of 
meats and fish the loss ranges from 40-50% [60]. On the opposite end however, fruits and 
vegetables are common choices that contain high folate levels and have been shown to 
offer protection against the onset of cardiovascular disease [15].  
For cyanocobalamin (B12) and pyridoxine (B6), it has been observed that elderly 
populations are usually lacking in these vitamins due to poor diets and failure to absorb 
them properly which adds to their apparent heightened age specific homocysteine levels 
[16]. The combination of these three nutrients is essential for proper managing of 
homocysteine levels [17]. In fact, cyanocobalamin (B12) is required for methionine 
synthase to function properly.  However it is important to note that the decrease in 
homocysteine levels does not repair the damage caused, nor does the decrease prevent 
recurrence of cardiovascular or neurovascular events- its control simply seems to prevent 
issues from arising [19,60]. On the contrary to the effects of proper folate and pyridoxine 
(B6) and cyanocobalamin (B12) consumption, some certain dietary foods can lead to a 
marked accumulation of homocysteine. Increased consumption of coffee, ethanol, red 
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meats, fish, chicken, cheese, and eggs as opposed to plant protein sources can cause 
increased homocysteine levels [18].  
The relationship between increased exercise and homocysteine levels is widely 
debated, but important to mention when researching homocysteine and its effects. The 
results of numerous exercise studies seems to indicate that chronic, higher intensity 
exercise speeds up the metabolism of methionine to homocysteine leading to increased 
levels in individuals. Similarly individuals who had sedimentary lifestyles before 
beginning a moderate exercise regimen composed of walking for approximately 30 
minutes, several times a week, reported having lower homocysteine levels as compared to 
the beginning of the trial [18]. These general studies however should be taken lightly in 
that they fail to encompass a number of factors that could influence homocysteine levels 
such as: stress, general health to begin with, accuracy of exercise reporting, creatinine 
levels, and many more. Besides the inconsistency in exercise effectiveness in moderating 
homocysteine levels, numerous reports support the idea that exercise improves both 
cardiovascular and nervous system function as a whole.    
Gender also plays a role in blood concentrations of homocysteine. From several 
studies, premenopausal women are known to be protected from coronary disease 
compared to postmenopausal women suggesting the role of estrogen in vascular health 
[24]. Estrogen and homocysteine studies suggest that higher estrogen status “is associated 
with lower homocysteine levels independent of nutrition and muscle mass and may 
explain the reported male-female difference in total homocysteine concentration” [20,21]. 
Estrogen levels also seem to play a role in increased folate utilization, which would assist 
the remethylation of homocysteine [22]. From the differing hormone levels, the 5-8 fold 
Kyles 7 
 
risk of coronary artery disease of males aged 25-55 years compared to females may be 
explained by the fluctuating homocysteine levels associated with estrogen. The difference 
in levels may also be associated with higher muscle mass in men. The formation of 
muscles is associated with increased creatine/ creatinine synthesis which runs 
simultaneously to homocysteine formation [33].  
The last major contributor to homocysteine levels is smoking. Smoking 
exacerbates the effects of homocysteine in that it also acts independently from other 
vascular risk factors. It is a well-known fact that people who smoke have a higher 
occurrence of a number of cardiovascular and neurovascular issues and it comes to no 
surprise that this risk is parallel to their overall homocysteine levels. Smoking has also 
been shown to change plasma chemistry affecting the thiol redox balance and also may 
inhibit methionine synthase [34]. A comparison study’s results between smokers and 
non- smokers is shown below [23] [Table 1]. However it is important to note that this 
study did not base line for diet, but the p-values for the results suggest significance 
outside of this influence.  
 
 
Table 1: Comparison between non-smokers and smokers with levels of homocysteine, folic acid, and vitamin B12 represented. 
The results were obtained from Mohamed Fadhel Najjar, et al. "Effect of Cigarette Smoking on Plasma Homocysteine 
Concentrations."  
Homocysteine, µmol/L 18.46 12.75 0.04 
Folic acid, nmol/L 4.30 4.45 0.56 
Vitamin B12, pmol/L 363.94 407.45 <10-7 
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Table 2: The three main classes of plasma homocysteine. Relative to 12 µmol/L obtained from Mudd SH, Finkelstein JD, 
Refsum H, Ueland PM, Malinow MR, Lentz SR, et al. Homocysteine and its disulfide derivatives: a suggested consensus 
terminology. Arterioscler Thromb Vasc Biol 2000;20: 1704-1706. 
III: Important Forms of Homocysteine in the Blood: 
The sources listed above all provide for increases in homocysteine levels. Once 
concentrations of homocysteine overwhelm the mechanisms meant to keep it in check, 
homocysteine can take several damaging forms. These main forms are protein bound, 
free oxidized, and free reduced, and together encompass total homocysteine levels [Table 
2]. 
The most common form of homocysteine found in plasma is when it is bound to 
proteins such as albumin. It also can bind to other proteins such as ɣ-globulin, α-
glycoprotein, transthyretin, and high-density lipoproteins, but in lessening levels. The 
combination of these constitutes approximately 80% of total plasma levels [27, 28]. 
Albumin is particularly prone to homocysteine due to a free cysteine residue at an N-
terminal position where oxidation with homocysteine’s sulphur can occur. These protein-
homocysteine compounds are termed S- Homocysteinyl-Protein and are generally 
considered to be biologically unreactive [27]; however this process of 
homocysteinylation can alter metabolizing agents such as homocysteine’s own 
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endogenous metabolizing enzyme cystathionine γ-lyase which is responsible, among 
other things, for the catalysis of L-cystine to hydrogen sulfide [42]. The alteration and 
substrate inhibition of this enzyme may limit the supply of the potent anti-oxidizing agent 
and vaso-relaxing agent hydrogen sulfide, a subject we discuss in section V [44].   
The next form is free oxidized homocysteine which occurs when two 
homocysteine molecules interact forming a new homocystine compound or when 
homocysteine interacts with cysteine forming a homocysteine-cysteine molecule. These 
compounds are formed due the chemical reactivity of homocysteine at physiological pH 
causing the thiols to form a bridge creating the homodimer homocystine or a 
homocysteine bound to a cysteine [28]. The reaction is shown in the following 
generalized formula:  2 R-SH = R-SS-R + 2H+ + 2e-. These free electrons can then react 
singly or in pairs in reducing oxygen; the product is superoxide if one electron reacts and 
a peroxide if 2 elections react. Oxidized homocysteine is relatively reactive due to 
oxidative stress, but the free reduced form of homocysteine is the most reactive of them 
all. 
The last major form of homocysteine in the plasma is free (reduced) 
homocysteine and it exists in less than 2% of total levels [28]. There is evidence 
suggesting that the free thiol form of homocysteine is more harmful than the protein 
bound and the disulfide species described earlier [28]. Normally free homocysteine binds 
to proteins or interacts with itself or cysteine but some is left over. The left over is termed 
reduced homocysteine and has a highly reactive free thiol group that can participate in 
redox reactions [28,29]. Several studies have shown that this free thiol is associated with 
endothelial dysfunction in humans while the protein and disulfide forms did not 
Kyles 10
contribute significantly [31, 32]. The free reduced form is mainly oxidized to the 
disulfide forms. However some of this free form is converted into homocysteine’s 
thiolactone [32].  
Homocysteine’s thiolactone is related to serum levels of free reduced 
homocysteine; homocysteine’s thiolactone is synthesized by methionyl-tRNA synthetase 
(MetRS) in human endothelial cells, as well as several others such as fibroblasts and 
breast cancer cells [37]. It is important to note that homocysteine’s thiolactone level of 
0.2 nM in normal individuals increases to 14.4 nM and 11.8 nM in CBS and MTHFR 
mutated patients respectively [36]. Although, as previously mentioned, patients with 
CBS/ MTHFR issues show elevated total homocysteine levels, the increase of thiolactone 
occurs significantly outside of the total increase showing its importance in vascular issues 
associated with hyperhomocysteinemia [36]. Because free reduced homocysteine and its 
thiolactone are related, thiolactone proves to be highly reactive and may provide a 
mechanism of hyperhomocysteinemia’s vascular effects and will be discussed later 
[36,37]. 
As presented, numerous meta-analysis and cohort studies have shown a link 
between homocysteine and increased vascular risks. There are many sources of increased 
homocysteine levels, ranging from diet to genetics, and it is clear that these increased 
concentrations summate towards the deregulation of proper vascular and nervous 
Homocysteine  Homocysteine thiolactone 
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function. In this study we aim to show the negative effects of homocysteine through the 
vascular system first and then in its apparent implication in memory by experiment.  
IV: Homocysteine and Endothelial Dysfunction: 
The first reports linking plasma levels of homocysteine to cardiovascular risks 
were published on mentally retarded children in 1962. Physicians initially noticed high 
concentrations of homocysteine in the children’s urine, a condition called 
homocystinuria, and in later years found the gene coding for cysteine-beta synthase 
(CBS) to be lacking in many cases [8]. Mudd and colleagues described four major 
hallmarks of the CBS deficient patients: ocular lens dislocation, skeletal abnormalities, 
differing degrees of mental retardation, and thromboembolic disease which was often the 
cause of their premature deaths [50]. Also Mudd, and later McCully documented 
widespread vascular atherosclerotic lesions in autopsies of hyperhomocysteinemic 
patients [50]. However, at the time many believed that hyperhomocysteinemia simply 
blended in with other risk factors such as HDL and LDL in causing vascular issues; but 
we know now this is not entirely the case.   
Upon further investigation it was found that children with defects in CBS, and 
subsequently high levels of circulating homocysteine, frequently had thromboembolic 
events. This finding was later re-confirmed by Wilcken and Wilcken in 1976 when they 
linked altered homocysteine metabolism to coronary artery issues [9]. In a landmark 
study in 1985, Mudd and colleagues studied 600 patients and their response to high doses 
to pyridoxine (B6) to test if the reduction of homocysteine was parallel to reduced 
vascular problems; they found risk was significantly reduced in the treatment population 
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[51]. Also the previously noted concern for homocysteine masking by other risk factors 
was disproven by the meta-analysis of Boushey et al in 1995, and in later studies of the 
2000s which concluded that the association between plasma homocysteine levels and 
cardiovascular problems remains strong even after adjustment for other risk factors 
[10,67].  
From the compiled information linking homocysteine to cardiovascular issues the 
question of how does homocysteine specifically act on the cardiovascular system arises. 
To understand the routes of action a brief review of cardiovascular components is needed. 
The cardiovascular system is essentially composed of the heart, the arteries and veins, 
and the blood. All of these parts work in cooperation to create circulation. The functional 
unit of each of these components is primarily the vascular endothelial cell. Vascular 
endothelial cells provide lining for capillaries, veins and arteries, and the thick walls of 
the heart and their upkeep is essential to a healthy cardiovascular system. Congruently the 
majority of cardiovascular problems arise from issues in endothelial lining. For the 
purpose of this report we will limit the discussion to how homocysteine affects the 
endothelial lining in explaining its negative impacts.  
The major route of homocysteine acting on endothelial cells is widely contested, 
but recently increased evidence has confirmed its importance. In this section it is 
important to note that many of homocysteine’s effects, especially in the formation of 
atherosclerosis, can be activated by other means besides a lining breech [69]. In this 
article we will entertain that homocysteine effects the endothelial vessel lining in four 
major ways: by increasing blood pressure, by activating platelet aggregation, by oxidative 
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stress release and MMP activation by monocyte adhesion, and by inducing smooth 
muscle proliferation. 
The first route homocysteine can act on the endothelial lining is by increasing 
blood pressure. In the cardiovascular system pressures differ greatly with each heartbeat 
as expressed by the systolic (maximum) and diastolic (minimum) readings of a blood 
pressure cuff. The endothelial lining is expected to undergo functional adaptations to 
accompany the pressure load. The development of blood pressure issues arises when this 
adaptation is abused and elasticity is lost or structural components of the endothelium are 
compromised providing resistance. These developments occur 95% of the time from 
idiopathic or multifactorial sources [43]. Because blood pressure can compromise and 
activate a plethora of endothelial issues, it is important to note how homocysteine may 
play a role in its increase.     
Homocysteine has been shown to increase blood pressure by the “Hordaland 
Study” in which 16,000 people aging from 40-67 years old with no history of 
hypertension were tested and homocysteine levels were found to be positively correlated 
with pressure levels [45]. Several mechanisms have been proposed to explain this find 
including: increased vascular hypertrophy (enlargement of endothelial cells), reduced 
availability of endothelial nitrous oxide and H2S (vaso-dilating agents), increased 
vascular smooth muscle cell proliferation (leading to tightness), antagonizing the smooth 
muscle cells (thickness/ vasoconstriction from angiotensin), increased intimal-medial 
thickness by amplified levels of collagen impairing vascular compliance (less elasticity), 
and increased intracellular calcium levels affecting vascular muscle cell tension (muscles 
squeeze vessels) [42]. Much research needs to be done elucidating the exact mechanisms 
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of each. The rise in tension and narrowing of the vessels caused by homocysteine and 
increased blood pressure can lead to an increase in thrombotic events such as stroke and 
heart attack.  
The second route homocysteine can act on the cardiovascular system is through 
increased platelet aggregation. This theory of homocysteine’s influence on clot formation 
was first proposed by McDonald et al. in 1964 when he noticed an increased adhesion of 
homocysteine’s platelets on a glass surface [51, pg 415]. As previously mentioned 
homocysteine can become autoxidized in the blood forming dimers and also can be 
bonded to proteins. It can also be converted into a thiolactone [25]. This molecule will 
become important with its interactions with platelets.  
Platelets, also known as thrombocytes, are involved in the clotting mechanism. 
Individually platelets contain integrin molecules, as well as many other receptors, on their 
surfaces. One of these integrin surface proteins is glycoprotein IIb/IIIa (integrin αIIbβ3) 
[38]. This integrin is the most abundant platelet adhesion molecule and is found in a 
density of approximately 80,000 receptors per platelet [52]. During vessel injury and clot 
formation this receptor’s job is to show affinity and bind to fibrinogen and also to 
activate von Willebrand factors which exponentially increase the “stickiness” of a platelet 
aggregate [46]. These factors also increase the platelets affinity to exposed collagen on 
the endothelium which rapidly occurs in injuries where the basal collagenous membrane 
of the vessel is exposed.  
In patients with hyperhomocysteinemia, it has been shown that homocysteine and 
its thiolactone both antagonize integrin αIIbβ3 changing its confirmation permitting 
binding of its ligand, fibrinogen [38]. This primarily occurs by homocysteine’s 
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thiolactone interacting with a cysteine group within integrin inadvertently activating it 
[52]. It is interesting to note that integrin αIIbβ3 has been shown to have thiol isomerase 
activity, which in normal processes acts in appropriately changing confirmation to an 
active state, so it is plausible that thiolactone could interact to inadvertently activate this 
adhesion receptor [52,53]. The binding of integrin αIIbβ3 to fibrinogen creates a cross 
bridge to another platelet causing the beginnings of a clot [39]. This ligand binding in 
turn activates alpha granules inside each platelet, which release p-selectins that signal 
other platelets to become more “sticky” [38, 39, 40]. Several studies show that increased 
levels of homocysteine and its thiolactone augment platelet activation causing the 
platelets to form clots more readily [38]. Not surprisingly in these studies thiolactone was 
found to be more effective in modulating platelet adhesion [38]. If these clots reach sizes 
of arterial blockage, heart attacks and strokes can occur by putting stress on weak spots in 
the endothelial lining of vessels, especially in a capillary/ micro vessel setting, as we will 
see in the microvasculature of the brain later on. This stress is a topic that is essential in 
understanding homocysteine’s negative vascular effects and also in its neuronal 
pathology.                  
As previously mentioned, blood pressure is markedly increased in 
hyperhomocysteinemic patients which is caused by an increase in collagen deposition in 
the extra-cellular matrix among other factors [47]. This increase in endothelial tension 
can cause atherosclerotic injuries at bifurcated vessels where pressure is the highest. 
These micro lesions on the endothelium lining then expose collagen and subsequently 
create a “rough” patch on the otherwise smooth lining. This rough spot creates a perfect 
place for the platelet’s increased affinity for other platelets, collagen, and stickiness to 
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combine. This complex of platelet’s can then aggregate creating thrombotic and 
atherosclerotic events leading to increased risks of heart attacks and stroke.  
The third route to be discussed on homocysteine’s interaction with endothelial 
cells is autoxidation and MMP activation. Homocysteine’s autoxidation at physiological 
pH was previously explained through its homodimer formation and interactions with 
cysteine to form a homocysteine- cysteine molecule [28]. This creates either a superoxide 
or peroxide depending on how many electrons react with oxygen. The increased 
oxidative stress on endothelial cells induces the expression of several matrix 
metalloproteinases by mimicking an injurious environment.  
Matrix metalloproteinases are a family of endopeptidases that break down amino 
acids within proteins and can be thought of as protein “scissors”. Their primary job is to 
regulate the extracellular matrix, which in terms of endothelial cells, is the structural 
support that keeps vessels healthy. In events where these proteases are overly activated 
there is a marked decrease in vascular wall integrity [61]. Within the endothelial 
extracellular matrix two MMPs are of importance; these are MMP-2 and MMP-9. The 
reason that these two MMPs are of high importance is because they are the only ones 
capable of degrading collagen type IV and are classified as gelitanases which allow for 
easier determination of their activity in vitro by zymography. This interaction with 
collagen is especially important in capillaries and micro-vessels, a subject we will discuss 
later in relation to neuron microvascular health.  
In hyperhomocysteinemia these two MMPs have been shown to interact with 
endothelial tight junction proteins in capillary settings and increase permeability and 
leakage [48]. Also in knockout studies MMP-2 and MMP-9 have been implemented in 
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cardiac rupture after myocardial infarctions which suggests their role in major vessel 
structure and the creation of new vessels as well [49]. However, much about MMP 
activation in hyperhomocysteinemic events is not fully understood. There is some 
evidence supporting a hypothesis of MMP activation besides just saying, “reactive 
oxidative species activate MMPs,” which is a common phrase in oxidative studies of 
hyperhomocysteinemia. The activation of these MMPs may be generated by vascular cell 
adhesion protein (VCAM-1) and intercellular adhesion molecule (ICAM-1) being up-
regulated in hyperhomocysteinemia leading to increased monocyte and leukocyte binding 
[54, 55]. 
In normal individuals the site of endothelial damage is quickly relieved and 
suppressed to prevent vascular issues from arising. One step in this process is to help 
reduce the chance of infection by increasing the injured area’s affinity for monocytes. As 
previously mentioned, the blood is always circulating with each heartbeat and the injured 
site needs some way to stop these monocytes from simply rolling away- the answer is up 
regulation of the VCAM and ICAM receptors [39, 56]. In hyperhomocysteinemia, the 
vessels are stressed from increased pressure, reactive oxidative species, reduction of 
bioavailable NO, and increased cytokine concentrations which can mimic an inflamed 
injurious environment [54, 56, 62]. Due to this increased stress several studies have 
reported a drastic up-regulation in VCAM and ICAM and subsequently an increased 
binding of monocytes [54, 55, 57].  
Upon binding to the up-regulated VCAM and ICAM receptors, the monocyte 
undergoes diapedesis (intake during inflammation) into the sub-endothelial space where 
they convert into macrophages. During this process there is evidence that the binding of 
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monocytes to VCAM and ICAM stimulates their NAPDH oxidases to undergo a 
“respiratory burst” which is intended to destroy any pathogens around [56, 58, 59]. 
Normally this “burst” of reactive peroxidases and superoxides are kept in check by 
powerful antioxidants, but in a non-injured vessel who’s antioxidant systems are already 
compromised by the unavailability of NO (nitrous oxide) and possibly GSH 
(gluthionine), along with the increased affinity and occurrence of monocyte adhesion 
could lead to a situation where reactive oxidative species are increasingly prevalent. Also 
the activation of these cells leads to a release cytokines, chemokines, and growth factors 
which gives rise to an inflammatory environment [62]. This increase of reactive species 
would cause the activation of MMP-9 and MMP-2 to begin remodeling the endothelial 
extracellular matrix, basal membranes, and tight junction proteins which can cause 
increased permeability of LDL cholesterol to enter the sub-endothelial level forming a 
“bubble” in the intima as shown below [Figure 3].  
Figure 3: Formation of arterial blockage and thrombotic events. The endothelial is compromised leading to monocyte diapedesis and 
macrophage conversion by LDL into foam cells freeing cholesterol and increasing fatty buildup. Daniel J. Rader & Alan Daugherty 
Nature 451, 904-913(21 February 2008) 
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The fourth major route homocysteine interacts with the endothelial lining to be 
discussed in this report deals with smooth muscle cell proliferation. From studies of 
atherosclerosis it was found that often smooth muscle cells migrate to the sub-
endothelium in regions of vascular injury [62]. Normally these cells circulate as 
progenitor cells and are activated by platelet derived growth factor which can be found in 
alpha granules distributed by activated platelets, which as explained earlier, can be 
induced by homocysteine’s interactions with integrin [38, 65]. This migration is also 
followed by a marked increase in their proliferation in hyperhomocysteinemic conditions 
[64]. This increased proliferation creates increased amounts of layers thus decreasing the 
size of the vascular lumen creating an environment ripe for atheroma, which is the 
swelling of artery walls and accumulation of plaque [60].  
The route of this activation is still currently being investigated and involves many 
key players. However it is clear that homocysteine can induce connective tissue growth 
factor (CTGF), a potent stimulator of smooth muscle proliferation in the vascular intima. 
Several pathways in hyperhomocysteinemic conditions lead to the up-regulation of 
CTGF. These up-regulations seem to be caused by a possible stimulation of PKC by 
homocysteine and also by the release of ROS, especially H2O2 and its apparent direct 
activation of Janus Kinase 2 and 3 (JAK2/JAK3) which leads to CTGF and cytokine 
release [66,68]. Both of these pathways are shown to be up-regulated in 
hyperhomocysteinemic conditions and cause an increase in the “layers” of muscle cells 
and collagen deposition which affect proper vessel structure as shown below in figure 4. 
The image below represents smooth muscle proliferation after injury and shows the result 
of “increased layers.” 
Kyles 20
The four routes of homocysteine’s interactions with the endothelial cell can affect 
both its proper function and structure. In summary these were discussed in four routes: 
increased blood pressure, activated platelet aggregation, oxidative stress release and 
MMP activation by monocyte adhesion, and smooth muscle proliferation. However when 
dealing with homocysteine in the neuron and memory impairment the vessels are merely 
half the picture, the other half is the neuron itself and through research conducted at the 
University of Louisville the intricate relationship between micro-vessels, the neuron, and 
their role in memory was explored.    
V: Homocysteine, the Blood Brain Barrier, and Memory Impairment- 
University of Louisville Summer Research Program: 
Homocysteine and its effect on vascular function are not limited to the endothelial 
cells, but can also be implicated in proper neuronal function. In a review of neurological 
diseases it was found that homocysteine was elevated when cognitive decline occurred 
[70]. Initially an increase of homocysteine levels was reported by Regland and colleagues 
in patients with dementia in 1990 [70, 71]; since then, the link has become clearer with an 
increased interest in the research of elderly conditions such as Alzheimer’s and 
Parkinson’s [72]. In one study a cohort of 321 men were assessed for diet, folate, B 
Figure 4: Pictures of mice arteries comparing smooth muscle proliferation after a denudation injury. [A] is the injured vessel [B] 
normal. These images are to show vessel narrowing by SMC proliferation. Findeisen, Hannes M, et al. "Epigenetic Regulation of 
Vascular Smooth Muscle Cell Proliferation.”  
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vitamins, and homocysteine over the course of 3 years with increments of examination 
through the Mini-Mental State Examination; the group found that there was a strong link 
between a decreased cognitive score and increased homocysteine levels and interestingly, 
they also found that folate intake seemed to offset this decline [73]. Along with a plethora 
of other studies, the link between homocysteine and its metabolism has been connected to 
cognitive impairment. The mechanism of this supposed decline is more appropriately 
addressed through the memory center of the brain. 
 The role of the hippocampus was discovered by the famous case of Henry 
Molaison and his surgical removal of the region to alleviate seizures. His surgery 
occurred in 1953 and removed most of his hippocampus and surrounding tissues. After 
his surgery scientists found he suffered anterograde amnesia, which is the inability to 
form new memories, and moderate retrograde amnesia, which deals with past memories 
[74]. This finding started an intense rise of memory related research and also serves as a 
prime starting point in investigating homocysteine’s apparent impact on memory 
formation. 
During research conducted at the University of Louisville’s Cardiovascular and 
Physiology Summer Program for Undergraduate Students 2013, the role of homocysteine 
in cognitive decline and the possible treatment with hydrogen sulfide was investigated. 
This paper will give a brief explanation of some of the findings during the three month 
experiment, but in order to understand the experiment more fully a brief summary of 
what was done is in order.  
In the experiment there were six treatment groups (mice) that were injected with 
the following respective compounds intracranially at the start of the trial: artificial 
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cerebrospinal fluid (aCSF), homocysteine (Hcy), homocysteine+ NaHS, homocysteine+ 
MK801, MK801 per se, and NaHS per se. The NaHS (sodium hydrogen sulfide) and 
MK801 treatments were continued intraperitoneally for a 7 day period. After the 7 day 
period was finished, the animals were removed and subjected to novel object tests for 
memory, depression tests, tail cuff blood pressure tests, Doppler fluorometry tests, and 
finally sacrificed for immunohistochemistry tests such as western blots, semi-quantitative 
PcR, zymography, and slide tissue staining.  
In our particular project we set out to confirm the reported effects homocysteine 
had on the hippocampus as well as to determine if hydrogen sulfide could attenuate the 
negative effects through mitigation of the NMDA receptor as well as reduce the oxidative 
stress and tension on the micro-vessels through its strong antioxidant properties and by 
doing so, hopefully improve memory [81]. Also we wanted to investigate homocysteine’s 
role in altering the relationship between the neuron and the blood brain barrier and to see 
if hydrogen sulfide could prevent this alternation from occurring.  The reason MK801 
was used was to help determine whether the NMDA receptor was indeed the receptor 
orchestrating homocysteine’s negative effects on the neuron because MK801 is a known 
antagonist to the NMDA receptor [82].      
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As aforementioned, homocysteine has been linked numerous times to a decline in 
cognitive functions both in human and animal studies. In our cognitive tests, our results 
were congruent with the studies mentioned above by showing an increase in cognitive 
impairment with the rise of homocysteine levels [Table 3].  
Alongside this supposed alteration of cognitive function is a marked increase of 
depression which suggests a further role of homocysteine in normal brain function. 
Several studies have shown correlation between elevated homocysteine and increased 
occurrence of depression [77-78]. One study sampled 3,752 men aged 73 years or older 
and found that higher levels of homocysteine increased the risk of depression and 
lowering their homocysteine levels within normal range reduced the risk by 20% [79]. 
This relationship can be attributed to the anxiety of stroke and cardiovascular events 
which have been known to induce depression in patients, but there seems to be a 
Table 3: Novel object test results in terms of recognition index which is the total time spent exploring the novel object 
as compared to the old one. It discerns how well the mice can determine the difference between an old memory and a 
new one. Significance of Hcy was compared to the aCSF control and the treatment NaHS and MK801 are compared to 
the Hcy group. 
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biochemical role outside of these psychological affects that is attributed to neurotoxicity 
[79, 80]. In our mouse models we found similar results through a depression swim test 
[Table 4]. 
The hypothesis explaining this cognitive impairment and depression by 
homocysteine was based upon two routes that both summated to neurotoxicity. The first 
route was through homocysteine’s effect on the blood brain barrier and its micro-vessels. 
The second route homocysteine was through the neuron by its ability to induce an 
excitatory ion influx by antagonizing the NMDA receptor and overexciting the 
mitochondria. Our central hypothesis is shown below [Figure 5].                   
Table 4: Results of the depression swim test are expressed in average seconds “floating” which is representative of 
depression in mice. Significance of Hcy was compared to the aCSF control and the treatment NaHS and MK801 are 
compared to the Hcy group.  
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The first route we examined was how homocysteine interacted with the blood 
brain barrier. The blood brain barrier is a delicate system of capillaries that supplies 
nutrients and proteins to the neuron. One hallmark of capillary structure is a series of 
tight junctions that provide strict control of cellular transport by forming an almost 
impenetrable, closely regulated zone of transport [75].  The relationship between the 
capillary and the neuron is bridged by astrocytes whose primary job is to ensure the 
proper delivery of nutrients and signals, as well as the expulsion of waste products [76]. 
These astrocytes sit just behind the endothelial lining in the basil lamina where they 
branch out with end feet to create more surface area. Astrocyte end feet, termed glia 
limitans, are often associated with the formation of tight junctions between the 
endothelial cells and are often found in close contact [75]. 
Figure 5: Hypothesis for homocysteine’s interaction with the neuron ultimately leading to cognitive impairment.  
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In order to understand how homocysteine was inducing its effects on micro 
vessels and the blood brain barrier (BBB) a series of stress tests, slide staining, western 
blots, and PcR were used to test our hypothesis. The first of these tests was a fluorometric 
experiment to investigate the integrity of the BBB after the 7th day of the trial. The results 
of the test confirm our hypothesis by showing an increase in permeability of the vessels 
in the homocysteine group and the reduction of permeability by the NaHS group. The 
results are shown below in Table 5. 
To explain this increase of leakage we wanted to see if MMP activation played a 
role in reducing vascular integrity by compromising both the basal lamina and the tight 
Table 5: Results of blood brain barrier stress test induced by histamine vasodilation. Notice the increased permeability 
of the Hcy group and the subsequent normality of the NaHS group. The increased “fuzziness” and brighter areas are 
the dye leaking out of the vessels showing permeability issues.    
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junctions of the micro-vessels to which the blood brain barrier is known for. To test this 
we used PcR and western blotting to examine if up regulation and increased expression of 
MMP occurred along with zymography, to test its activity. Also this increased leakage 
was thought to interfere with the neurocoupling between the neuron and the vessels by 
way of astrocyte retraction. To test this we slide stained portions of the hippocampus for 
VE-Cadherin and GFAP and viewed them under a fluorescent microscope. VE-Cadherin 
is used to show vessel strength and healthiness of vessel junctions (red) [83]. GFAP 
stands for glial fibrillary acidic protein and is used as a marker for astrocytes (green) [84]. 
The results for these prospective studies are shown below in Tables 6, 7, and 8.   
Table 6: The results of MMP PcR (top) and western blotting (bottom). Right is the relative increase or decrease in 
expression. GFAP is shown as an indicator of proper concentrations. Note the decrease hydrogen sulfide has on MMP 
expression. 
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Table 8: The slide stains are of vessels in the hippocampal region. The first blue stain is DAPI for nucleus staining. The green 
second column is GFAP. Take note of the astrocyte retreat into the tissue in Hcy. The red third column is VE-Cadherin 
showing structural integrity of vessels and TJP. Notice Hcy’s effect on vessel integrity and NaHS revival. The last column is a 
merge of the results to help show location of vessels.  
Table 7: The white arrows point to the active form of MMP-9, and the dash below signifies the activity of MMP-2. Both 
activities are increased in Hcy and reduced in NaHS treatment. The MMP break down the dye and reveal light below 
showing if the protein is active.  
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These results suggest that homocysteine is activating MMPs, which then degrade 
the tight junction proteins and basal lamina of the blood brain barrier, causing a retraction 
of astrocytes and an increase in permeability, thus disrupting neurocoupling causing the 
link between the neuron and the vessel to be broken which agrees with our proposed 
mechanism. This subsequent breaking can have negative effects for the health of the 
neuron because it is starved for nutrients and believes the disruption of the blood vessels 
to be an injurious event, possibly creating a neurotoxic environment where cellular waste 
can compile. However the route of homocysteine through the vessels is not the only way 
homocysteine can induce neurotoxicity in hippocampal neurons [85].  
The second route that homocysteine can take in decreasing cognitive ability by 
neurotoxicity is by acting directly on the neuron itself. This process occurs by its 
interaction with the NMDA receptor [86, 87]. The NMDA receptor is a glutamate 
receptor heavily involved in proper ion movement, especially in the context of calcium 
importation [90]. Because of this the NMDA plays a major role in memory and learning 
by long and short-term potentiation of nerve signals, it is widely considered one of the 
most important receptors in the brain [90]. Homocysteine has been known to antagonize 
the NMDA receptor located on the external membrane of the neuron. The opening and 
increased expression of this receptor causes a massive importation of calcium into the 
neuron and induces several downstream signals that affect the mitochondria. The 
increased intracellular calcium excites the mitochondria causing it to release reactive 
oxidative species and cytokines leading to a neurotoxic environment and possibly cell 
death [88].  
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To combat this excitatory effect the neuron implements mitophagy, the process of 
removing mitochondria, to remove the defective “power factory” and reduce the threat of 
total cell destruction [89]. One major event in our hypothesis is the stimulation of the 
NMDA receptor and is why we chose MK801 to act as the negative control. Also 
mitophagy and the cytotoxic release of the mitochondria induced by excitatory calcium 
were important to our hypothesis [91, 92, 93]. The result of an intracellular calcium test is 
shown in Table 9. The results of our PcR and western blot test to show mitophagy/ 
autophagy, increased release of ROS, and NMDA activation are shown in Tables 10 and 
11.
Table 9: Intracellular Calcium levels measured in hippocampal regions. Notice Hcy massive increase through NMDA 
antagonizing and NaHS’s apparent mitigation. Significance of Hcy related to aCSF control and Hcy+ NaHS related to 
Hcy.   
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Table 10: Semi Quantitative PcR results: LC3 is an autophagy marker and its up-regulation is indicative of neuronal 
mitochondrial destruction. NOX2 marks for NADPH oxidase and reactive oxidative species. SOD2 marks 
mitochondrial superoxide dismutase which is active in removing reactive oxidative species. P62 is an autophagy 
marker whose decrease is indicative of autophagic occurrences. GAPDH is baseline for loading.   
Table 11: Western Blot Results: NR1 is a subunit of the NMDA receptor whose increase in Hcy in concurrent with its 
excitatory effects; NaHS treatment reduces increase. P62 is an autophagy marker whose decrease is indicative of 
autophagic occurrences.  SOD2 marks mitochondrial superoxide dismutase which is active in removing reactive 
oxidative species. GAPDH is loading concentrations for baseline.  
These results help to confirm our hypothesis. The increased level of intracellular 
calcium is a hallmark of antagonizing the NMDA receptor. This increase of calcium can 
alter synaptic function and lead to improper signaling which ultimately affects the proper 
formation of memories [93]. We confirm the antagonization with NR1 which is a subunit 
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of the NMDA receptor. NR1’s increase in expression is indicative of its excitation [91]. 
The increased expression of autophagy and mitochondrial dismutase markers is a sign of 
neurotoxicity as well as mitochondrial damage [91, 92]. Also in our experiment we found 
that ATP concentrations in the hippocampal regions were significantly decreased in the 
homocysteine treatment group as compared to the control. This decrease in ATP is yet 
another indicator that the neuron’s internal environment is being affected by the influx of 
calcium as well as the broken neurocoupling between the vessels.    
VI: Conclusion:  
 Homocysteine’s wide range of negative effects gives rise to its involvement in the 
possible pathologies of several systems. Ever increasing research on this molecule is 
finding implications in numerous diseased states and the mechanisms controlling them. In 
terms of the vascular system however, homocysteine’s effects on endothelial cells seems 
to be quite detrimental by simulating an injurious environment, but a great deal of 
research still needs to be done to elucidate the key molecular players and major routes of 
action. This increase in vascular stress can induce a myriad of complications ranging 
from stroke and atherosclerosis to coronary heart failure and degradation of the neuronal 
microvessels. In the nervous system, specifically the neurons of the hippocampus, 
homocysteine’s effects follow the route of excitatory theory by antagonizing the NMDA 
receptor causing an increased occurrence of mitophagy and autophagy by way of calcium 
importation. The degradation of mitochondria and generation of reactive oxidative 
species paired with the altercation of the delicate astrocyte connection to the microvessels 
provides a suitable mechanism of cognitive decline by means of neurotoxicity.  
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 All in all the control of homocysteine levels in one’s life can be easily 
accomplished by practicing a balanced diet with regular exercise. The simple addition of 
B vitamins and folic acid to diets have been shown to significantly reduce the onset of 
several vascular issues as well as to lower blood concentrations of homocysteine. Garlic 
and its stimulation of hydrogen sulfide production has also been shown to mediate 
homocysteine’s negative effects within the brain by inducing glutathione production and 
mediating the NMDA receptor [94]. From the broad range and sharp increase of 
homocysteine research, it seems as if it will play a much bigger role in the future of 
medicine, and may someday pass cholesterol as a biomarker for general vascular health. 
Keeping an eye on homocysteine would be a wise decision for students entering the 
medical profession and the continuation of its research is sure to produce some 
fascinating results.           
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